文献速递消化道肿瘤与早癌

c-Met作为肝细胞癌治疗靶点的最新进展

Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.
PubMed 文献 · Hepatology · 2018-02-01

综述指出异常c-Met活性参与肝细胞癌发生,但非选择性激酶抑制剂(tivantinib、cabozantinib、foretinib、golvatinib)临床试验至今未显示出显著疗效,可能与试验设计、未按肿瘤c-Met状态筛选患者及脱靶活性有关;选择性c-Met抑制剂(tepotinib、capmatinib)可达到预测完全抑制肿瘤c-Met活性的剂量,早期试验初步结果显示在Child-Pugh A肝功能患者中具有抗肿瘤活性且安全性和耐受性可接受,正在进行的试验旨在按肿瘤c-Met状态筛选患者中比较选择性c-Met抑制与标准治疗的疗效和安全性。

要点

  • 非选择性c-Met激酶抑制剂在肝细胞癌临床试验中至今未显示出显著疗效。
  • 选择性c-Met抑制剂可达到预测完全抑制肿瘤c-Met活性的剂量。
  • 早期试验初步显示选择性c-Met抑制剂在Child-Pugh A患者中安全性和耐受性可接受。

核心结论

  • c-Met抑制仍是肝细胞癌活跃的研究领域,正在开展精心设计的试验研究选择性c-Met抑制剂的获益。

研究设计与样本

  • 综述检索范围未在摘要中报告,本文汇总了非选择性和选择性c-Met抑制剂在肝细胞癌中的临床试验结果。

主要发现

  • 非选择性激酶抑制剂(tivantinib、cabozantinib、foretinib、golvatinib)在肝细胞癌患者中的临床试验至今未能显示出显著疗效。
  • 观察到的疗效缺乏可能归因于试验设计、未根据肿瘤c-Met状态筛选患者以及这些药物普遍的脱靶活性,后者可能提示c-Met抑制不完全。
  • 选择性c-Met抑制剂(tepotinib、capmatinib)可按预测达到完全抑制肿瘤c-Met活性的剂量给药。
  • 早期试验的初步结果提示选择性c-Met抑制剂在肝细胞癌中具有抗肿瘤活性,在Child-Pugh A肝功能患者中安全性和耐受性可接受。

关键数值与推荐

  • 非选择性c-Met抑制剂包括tivantinib、cabozantinib、foretinib和golvatinib。
  • 选择性c-Met抑制剂包括tepotinib和capmatinib。
  • 正在进行的试验设计为在根据肿瘤c-Met状态筛选的肝细胞癌患者中评估选择性c-Met抑制与标准治疗相比的疗效和安全性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 非选择性激酶抑制剂在肝细胞癌中的临床试验至今未能显示出显著疗效,可能原因包括试验设计、未根据肿瘤c-Met状态筛选患者以及这些药物普遍的脱靶活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant c-Met activity has been implicated in the development of hepatocellular carcinoma (HCC), suggesting that c-Met inhibition may have therapeutic potential. However, clinical trials of nonselective kinase inhibitors with c-Met activity (tivantinib, cabozantinib, foretinib, and golvatinib) in patients with HCC have failed so far to demonstrate significant efficacy. This lack of observed efficacy is likely due to several factors, including trial design, lack of patient selection according to tumor c-Met status, and the prevalent off-target activity of these agents, which may indicate that c-Met inhibition is incomplete. In contrast, selective c-Met inhibitors (tepotinib, capmatinib) can be dosed at a level predicted to achieve complete inhibition of tumor c-Met activity. Moreover, results from early trials can be used to optimize the design of clinical trials of these agents. Preliminary results suggest that selective c-Met inhibitors have antitumor activity in HCC, with acceptable safety and tolerability in patients with Child-Pugh A liver function. Ongoing trials have been designed to assess the efficacy and safety of selective c-Met inhibition compared with standard therapy in patients with HCC that were selected based on tumor c-Met status. Thus, c-Met inhibition continues to be an active area of research in HCC, with well-designed trials in progress to investigate the benefit of selective c-Met inhibitors. (Hepatology 2018;67:1132-1149).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Bouattour M, Raymond E, Qin S, et al. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. Hepatology. 2018. PMID: 28862760. doi:10.1002/hep.29496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。